← Back to Search

Decision-Making Support Tool for Lung Cancer (iDECIDE Trial)

N/A
Recruiting
Led By Donald R Sullivan, MD, MA, MCR
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Suspected lung cancer
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up 6 months
Awards & highlights

iDECIDE Trial Summary

This trial is testing a conversation tool to help patients with lung cancer make decisions about their treatment options. It is focused on patients with lower health literacy to see if they need different information to make treatment choices.

Who is the study for?
This trial is for individuals with suspected lung cancer who are fluent in English, have a life expectancy of more than 6 months, and are currently making treatment decisions. It's aimed at those with lower health literacy to help them understand their options. Non-veterans are specifically included to ensure the study's findings apply broadly.Check my eligibility
What is being tested?
The trial is testing a conversation tool designed to improve patient-centered outcomes by aiding decision-making in lung cancer treatments. The goal is to determine if this tool helps patients better understand and participate in choosing their treatment path.See study design
What are the potential side effects?
Since the intervention involves education and questionnaires rather than medical or drug treatments, there aren't direct side effects like you'd expect from medication. However, participants may experience stress or anxiety related to discussing their condition.

iDECIDE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am suspected to have lung cancer.

iDECIDE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Decision Satisfaction
Efficacy of a conversation tool on patients' knowledge of lung cancer
Satisfaction with Communication/Confidence in Decision
Secondary outcome measures
Acceptability
Decision Regret
Depression/Anxiety
+5 more

iDECIDE Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group I (decision aid)Experimental Treatment2 Interventions
Patients review decision aid.
Group II: Group II (standard of care)Active Control2 Interventions
Patients receive standard of care.

Find a Location

Who is running the clinical trial?

OHSU Knight Cancer InstituteLead Sponsor
226 Previous Clinical Trials
2,090,193 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
967 Previous Clinical Trials
6,845,376 Total Patients Enrolled
American Cancer Society, Inc.OTHER
224 Previous Clinical Trials
110,157 Total Patients Enrolled

Media Library

Health Promotion and Education Clinical Trial Eligibility Overview. Trial Name: NCT05407168 — N/A
Lung Cancer Research Study Groups: Group I (decision aid), Group II (standard of care)
Lung Cancer Clinical Trial 2023: Health Promotion and Education Highlights & Side Effects. Trial Name: NCT05407168 — N/A
Health Promotion and Education 2023 Treatment Timeline for Medical Study. Trial Name: NCT05407168 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are seniors eligible to volunteer for this experiment?

"This evaluation welcomes individuals who are at least 18 years of age and no older than 99."

Answered by AI

What primary goals is this clinical trial intended to achieve?

"The primary measurement of the trial's efficacy will be a Decision Satisfaction score, assessed over an approximate 6-month period. Secondary objectives include Quality of Communication (assessed via a 30-item Patient Assessment scale), Functional Assessment of Cancer Therapy -- Lung scale (27 items in total) and Patient Reported Shared Decision Making (measured with a 9 item questionnaire). All scoring systems are percentile based, wherein higher scores denote improved outcomes."

Answered by AI

What is the aggregate number of participants in this medical experiment?

"Affirmative. Based on information located on clinicaltrials.gov, this investigation is actively recruiting patients. It was first posted to the website October 31st 2022 and has since been modified November 23rd 2022. A total of 300 individuals are being sought out across two medical facilities."

Answered by AI

Is there a particular demographic that is eligible to participate in this experiment?

"This clinical trial seeks to enrol 300 individuals aged 18-99 with a lung carcinoma. Additionally, they must have participated in Aim 1 of the study, be proficient in English, expected to live longer than 6 months, scored more than 3 on the cognitive impairment screener and conversed about cancer treatment decisions with Aim 1 participants. Moreover, non-Veterans are also needed for this research initiative as their insights will make its results more applicable across different demographics."

Answered by AI

Are there any open enrollments for this investigative procedure?

"Affirmative, the information on clinicaltrials.gov suggests that this medical study is actively enrolling participants. The trial was initially posted October 31st 2022 and has been recently refreshed November 23rd 2022. This research requires 300 patients to be recruited from 2 sites."

Answered by AI
~196 spots leftby Sep 2026